The results show that a higher miR-155 and miR-132 expression in PBMC was associated to MS patients compared to healthy donors, but the results also showed two different patterns of miRNAs expression within MS patients: the first group over-expressed miR-155 and miR-132 in concert with up-regulation of the associated Th1/Th17 cytokine types such as IL-17a, IFN γ, TNFα but not IL-6, whereas the second MS group characterized by high levels of miR-26a, over-expressed only Th1 cytokine types such as IFN γ and TNFα. The gene discussed is IL6; the disease is myeloid sarcoma.